Pharmacology of myocardial calcium-handling

Wien Med Wochenschr. 2012 Jul;162(13-14):311-5. doi: 10.1007/s10354-012-0108-x. Epub 2012 Jun 16.

Abstract

Disturbed myocardial calcium (Ca(+)) handling is one of the pathophysiologic hallmarks of cardiovascular diseases such as congestive heart failure, cardiac hypertrophy, and certain types of tachyarrhythmias. Pharmacologic treatment of these diseases thus focuses on restoring myocardial Ca(2+) homeostasis by interacting with Ca(2+)-dependent signaling pathways. In this article, we review the currently used pharmacologic agents that are able to restore or maintain myocardial Ca(2+) homeostasis and their mechanism of action as well as emerging new substances.

Publication types

  • Review

MeSH terms

  • Acetanilides / pharmacology*
  • Adrenergic beta-Antagonists / pharmacology*
  • Amiodarone / analogs & derivatives
  • Amiodarone / pharmacology
  • Anti-Arrhythmia Agents / pharmacology*
  • Calcium / metabolism*
  • Calcium Channel Blockers / pharmacology*
  • Cardiomegaly / drug therapy
  • Cardiomegaly / physiopathology*
  • Cardiotonic Agents / pharmacology*
  • Digitalis Glycosides / pharmacology*
  • Dronedarone
  • Electrocardiography / drug effects
  • Heart Failure / drug therapy
  • Heart Failure / physiopathology*
  • Humans
  • Ion Channels / drug effects
  • Ion Channels / physiology
  • Myocardial Contraction / drug effects
  • Myocardial Contraction / physiology
  • Piperazines / pharmacology*
  • Ranolazine
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Tachycardia / drug therapy
  • Tachycardia / physiopathology*

Substances

  • Acetanilides
  • Adrenergic beta-Antagonists
  • Anti-Arrhythmia Agents
  • Calcium Channel Blockers
  • Cardiotonic Agents
  • Digitalis Glycosides
  • Ion Channels
  • Piperazines
  • Ranolazine
  • Dronedarone
  • Amiodarone
  • Calcium